semaglutide nash Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of suggest a beneficial role of GLP-1/glucagon agonism in NASH patients Semaglutide might be a key

Shima Hadidchi, MD , explains that Zepbound is a medication that goes beyond traditional GLP-1 treatments

We assessed target engagement of mGIP, hGIP and tirzepatide at the mGIPR with four complementary approaches: (1) ligand binding assays

Innate and adaptive immunity in atherosclerosis

This color is normal and expected

Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes

Several factors may indicate its time to consider discontinuation: Stable health improvements: Some individuals achieve significant weight loss, improved glycemic control, or normalized blood pressure and lipid levels, which may reduce the clinical need for continued medication